Immuneering Corporation Operating Cash Flow
Immuneering Corporation (IMRX) reported Operating Cash Flow of -$34.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Immuneering Corporation net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$16.50M.
- Immuneering Corporation net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$18.43M.
- Immuneering Corporation net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$9.84M.
- Immuneering Corporation net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$11.98M.
- Immuneering Corporation net cash provided by (used in) operating activities for fiscal 2025 was -$45.34M.
- Immuneering Corporation net cash provided by (used in) operating activities for fiscal 2024 was -$55.00M.
- Immuneering Corporation net cash provided by (used in) operating activities for fiscal 2023 was -$48.97M.
- Immuneering Corporation net cash provided by (used in) operating activities for fiscal 2022 was -$44.10M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$34.93M 10-Q · filed 2026-08-05 | -$44.78M derived: sum of 3 quarters · filed 2026-08-05 | -$56.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$18.43M 10-Q · filed 2026-05-15 | -$28.27M derived: sum of 2 quarters · filed 2026-05-15 | -$40.25M derived: sum of 3 quarters · filed 2026-05-15 | -$49.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$9.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$21.82M derived: sum of 2 quarters · filed 2026-03-06 | -$31.26M derived: sum of 3 quarters · filed 2026-08-05 | -$45.34M 10-K · filed 2026-03-06 |
| 2025-09-30 | -$11.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$21.42M derived: sum of 2 quarters · filed 2026-08-05 | -$35.50M 10-Q · filed 2025-11-12 | -$50.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$9.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$23.53M 10-Q · filed 2026-08-05 | -$38.04M derived: sum of 3 quarters · filed 2026-08-05 | -$51.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$14.08M 10-Q · filed 2026-05-15 | -$28.59M derived: sum of 2 quarters · filed 2026-05-15 | -$42.06M derived: sum of 3 quarters · filed 2026-05-15 | -$53.59M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$14.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$27.98M derived: sum of 2 quarters · filed 2026-03-06 | -$39.51M derived: sum of 3 quarters · filed 2026-03-06 | -$55.00M 10-K · filed 2026-03-06 |
| 2024-09-30 | -$13.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$25.00M derived: sum of 2 quarters · filed 2025-11-12 | -$40.49M 10-Q · filed 2025-11-12 | -$52.26M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$11.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$27.02M 10-Q · filed 2025-08-13 | -$38.79M derived: sum of 3 quarters · filed 2025-08-13 | -$50.82M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$15.49M 10-Q · filed 2025-05-05 | -$27.27M derived: sum of 2 quarters · filed 2025-05-05 | -$39.29M derived: sum of 3 quarters · filed 2025-05-05 | -$50.04M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | -$11.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$23.80M derived: sum of 2 quarters · filed 2025-03-20 | -$34.55M derived: sum of 3 quarters · filed 2025-03-20 | -$48.97M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$12.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$22.78M derived: sum of 2 quarters · filed 2024-11-13 | -$37.19M 10-Q · filed 2024-11-13 | -$48.94M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$10.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$25.17M 10-Q · filed 2024-08-06 | -$36.92M derived: sum of 3 quarters · filed 2024-08-06 | -$47.54M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$14.42M 10-Q · filed 2024-05-07 | -$26.17M derived: sum of 2 quarters · filed 2024-05-07 | -$36.79M derived: sum of 3 quarters · filed 2024-05-07 | -$46.24M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$11.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$22.37M derived: sum of 2 quarters · filed 2024-03-01 | -$31.82M derived: sum of 3 quarters · filed 2024-03-01 | -$44.10M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$10.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$20.07M derived: sum of 2 quarters · filed 2023-11-09 | -$32.35M 10-Q · filed 2023-11-09 | -$41.59M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$9.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$21.73M 10-Q · filed 2023-08-03 | -$30.97M derived: sum of 3 quarters · filed 2023-08-03 | -$40.00M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$12.28M 10-Q · filed 2023-05-04 | -$21.52M derived: sum of 2 quarters · filed 2023-05-04 | -$30.55M derived: sum of 3 quarters · filed 2023-05-04 | -$36.99M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$9.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$18.27M derived: sum of 2 quarters · filed 2023-03-06 | -$24.71M derived: sum of 3 quarters · filed 2023-03-06 | -$30.85M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$9.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$15.47M derived: sum of 2 quarters · filed 2022-11-10 | -$21.61M 10-Q · filed 2022-11-10 | -$27.07M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$6.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$12.58M 10-Q · filed 2022-08-10 | -$18.03M derived: sum of 3 quarters · filed 2022-08-10 | -$21.52M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$6.14M 10-Q · filed 2022-05-10 | -$11.59M derived: sum of 2 quarters · filed 2022-05-10 | -$15.08M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$8.94M derived: sum of 2 quarters · filed 2022-03-10 | -$14.62M 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$9.17M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$5.68M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |